DFMO treatment led to the recruitment of activated (IFNγ+) CD4+ T cells, CD8+ T cells and NK cells and an increase in tumour‐killing M1 macrophages in the tumour microenvironment of an ovarian cancer mouse model.171. The gene discussed is CD8A; the disease is neoplasm.